Mark N. Stein

Columbia University Irving Medical Center

Also affiliated with Herbert Irving Comprehensive Cancer Center

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 24 papers. Top paper: “A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial”.

A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial

The Lancet(2021)10.1016/s0140-6736(21)00152-5

N/A

6.9DataRank · unranked

283 citations

Catherine M. Tangen, Ian M. Thompson, Naomi Balzer-Haas, Daniel J. George, Daniel Y.C. Heng +15 more

Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

Journal of Clinical Oncology(2020)10.1200/jco.20.01652

N/A

3.5DataRank · unranked

138 citations

Rosa Nadal, Daniel M. Girardi, Scot A. Niglio, Lisa Ley, Lisa M. Cordes +30 more

Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial

The Lancet(2023)10.1016/s0140-6736(23)00913-3

N/A

1.4DataRank · unranked

49 citations

Catherine M. Tangen, Elisabeth I. Heath, Mark N. Stein, Maxwell V. Meng, Ajjai Alva +14 more

Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-2824

N/A

0.656DataRank · unranked

22 citations

Randy F. Sweis, J. Randolph Hecht, Reva Schneider, Mark N. Stein, Talia Golan +7 more

Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapy

The Prostate(2020)10.1002/pros.23948

N/A

0.629DataRank · unranked

13 citations

Samuel Pan, William D. Figg, Zoila A. Lopez‐Bujanda, Jonathan D. Strope, David H. Aggen +6 more

Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy

European Urology Open Science(2021)10.1016/j.euros.2021.09.015

N/A

0DataRank · unranked

19 citations

Emmanuel S. Antonarakis, Tina Mayer, Daniel H. Shevrin, Mark N. Stein, Ulka N. Vaishampayan +22 more

Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.270

N/A

0DataRank · unranked

9 citations

Catherine M. Tangen, Ian M. Thompson, Naomi B. Haas, Daniel J. George, Daniel Yick Chin Heng +15 more

EVEREST: Everolimus for renal cancer ensuing surgical therapy—A phase III study (SWOG S0931, NCT01120249).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.17_suppl.lba4500

N/A

0DataRank · unranked

39 citations

Catherine M. Tangen, Elisabeth I. Heath, Mark N. Stein, Maxwell V. Meng, Ajjai Alva +15 more

Single-Cell RNAseq Analysis Reveals Robust, Anti-PD-1-Mediated Increase of Immune Infiltrate in Metastatic Castration-Sensitive Prostate Cancer

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.05.06.490968

N/A

0DataRank · unranked

2 citations

Aleksandar Obradović, Matthew C. Dallos, Emerson A. Lim, Karie Runcie, Casey R. Ager +15 more

Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer

Cancer Cell(2023)10.1016/j.ccell.2023.10.006

N/A

0DataRank · unranked

77 citations

Aleksandar Obradović, Matthew C. Dallos, Emerson A. Lim, Karie Runcie, Casey R. Ager +16 more

Treatment-free survival (TFS) outcomes from the phase II study of nivolumab and salvage nivolumab + ipilimumab in advanced clear cell renal cell carcinoma (aRCC) (HCRN GU16-260-Cohort A).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.6_suppl.604

N/A

0DataRank · unranked

5 citations

Opeyemi A. Jegede, David F. McDermott, Naomi B. Haas, Mehmet Asım Bilen, Mark N. Stein +11 more

The PRIME-CUT study: A single-arm phase 2 study of ADT with PD-1 blockade and docetaxel in men with metastatic hormone-sensitive prostate cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e17089

N/A

0DataRank · unranked

2 citations

Matthew C. Dallos, Emerson A. Lim, Karie Runcie, Jianhua Hu, Israel Lowy +3 more

Data from Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer

(2023)10.1158/1078-0432.c.6529986

N/A

0DataRank · unranked

0 citations

Tiziano Pramparo, Amir Mortazavi, Scot A. Niglio, Joseph D. Schonhoft, Adam Jendrisak +26 more

Final results from a phase 1 trial and expansion cohorts of cabozantinib and nivolumab alone or with ipilimumab for advanced/metastatic genitourinary tumors

Research Square(2023)10.21203/rs.3.rs-2924051/v1

N/A

0DataRank · unranked

0 citations

Scot A. Niglio, Rosa Nadal, Andre R. Kydd, Nicholas I. Simon, Lisa Ley +36 more

Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes

Prostate Cancer and Prostatic Diseases(2024)10.1038/s41391-024-00797-0

N/A

0DataRank · unranked

23 citations

Allison Makovec, Andrew Elliott, Samuel Kellen, John R. Lozada, Ali T. Arafa +19 more

Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2023-008293

N/A

0DataRank · unranked

6 citations

Opeyemi A. Jegede, Naomi B. Haas, David F. McDermott, Mehmet Asım Bilen, Mark N. Stein +11 more

Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial

European Urology(2024)10.1016/j.eururo.2024.05.012

N/A

0DataRank · unranked

8 citations

Catherine M. Tangen, Elisabeth I. Heath, Shuchi Gulati, Mark N. Stein, Maxwell V. Meng +16 more

Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma

Cancer Discovery(2025)10.1158/2159-8290.cd-24-0991

N/A

0DataRank · unranked

38 citations

Lena V. Wirth, Kelly Street, Neil Ruthen, Opeyemi A. Jegede, Nicholas R. Schindler +22 more

Impact of pre-existing diabetes mellitus on acute care use in older patients with metastatic prostate cancer on androgen receptor signaling inhibitors.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.5_suppl.119

N/A

0DataRank · unranked

0 citations

Rohit Raghunathan, Karie Runcie, Shikun Wang, Jason D Wright, Alexander Z. Wei +3 more

Association of polypharmacy with acute care utilization in older adults receiving androgen receptor signaling inhibitors for metastatic prostate cancer.

JCO Oncology Practice(2025)10.1200/op.2025.21.10_suppl.518

N/A

0DataRank · unranked

0 citations

Rohit Raghunathan, Margaux Wooster, Karie Runcie, Shikun Wang, Jason D Wright +4 more

Association between medication burden and acute care use in older metastatic prostate cancer patients on androgen receptor signaling inhibitors

Cancer(2025)10.1002/cncr.70163

N/A

0DataRank · unranked

0 citations

Rohit Raghunathan, Karie Runcie, Margaux Wooster, Shikun Wang, Jason D. Wright +4 more

Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma 3574

The Journal of Immunology(2025)10.1093/jimmun/vkaf283.1362

N/A

0DataRank · unranked

0 citations

Miya B. Hugaboom, Kelly Street, Neil Ruthen, Opeyemi A. Jegede, Nicholas R. Schindler +22 more

1028P Clinical results of a pilot trial of GEN-009, a neoantigen vaccine containing immunogenic tumour specific neoantigens, in combination with PD-1 inhibitors in advanced cancers

Annals of Oncology(2020)10.1016/j.annonc.2020.08.1148

N/A

0DataRank · unranked

0 citations

Mark M. Awad, P. Twardowski, Romain Cohen, Mark N. Stein, Ammar Sukari +14 more

Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2891

N/A

0DataRank · unranked

48 citations

Tiziano Pramparo, Amir Mortazavi, Scot A. Niglio, Joseph D. Schonhoft, Adam Jendrisak +26 more